Rhythm Pharmaceuticals (RYTM) Operating Margin (2021 - 2026)
Rhythm Pharmaceuticals (RYTM) reported Operating Margin of 87.11% for Q1 2026, up 5662.0% year-over-year from 1.51% in Q1 2025, and down 5.97% on a QoQ basis from 82.2% in Q4 2025.
Rhythm Pharmaceuticals (RYTM) has 6 years of Operating Margin data on file, last reported at 87.11% in Q1 2026.
- Quarterly Operating Margin rose 5662.0% year-over-year to 87.11% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 90.89% (up 3524.0% YoY) and the FY2025 annual result came in at 101.19%, up 10284.0% from the prior year.
- Operating Margin fell to 87.11% in Q1 2026 per RYTM's latest filing, from 82.2% in the prior quarter.
- Across five years, Operating Margin topped out at 523.15% in Q4 2022 and bottomed at 3517.42% in Q1 2022.
- The 5-year median for Operating Margin is 143.73% (2025), against an average of 405.41%.
- The widest annual swing landed in 2022, when Operating Margin surged 9476258 bps; it then sank 69343 bps in 2023.
- Tracing RYTM's Operating Margin over 5 years: stood at 523.15% in 2022, then plunged by 133 bps to 170.28% in 2023, then jumped by 42 bps to 98.63% in 2024, then grew by 17 bps to 82.2% in 2025, then slipped by 6 bps to 87.11% in 2026.
- Per Business Quant, the three latest RYTM Operating Margin figures stand at 87.11% (Q1 2026), 82.2% (Q4 2025), and 102.64% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Rhythm Pharmaceuticals | 6.00 Bn | 5.66 Bn | 52.96 Mn | -87.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87.11% |
| Dec 31, 2025 | -82.20% |
| Sep 30, 2025 | -102.64% |
| Jun 30, 2025 | -93.39% |
| Mar 31, 2025 | -143.73% |
| Dec 31, 2024 | -98.63% |
| Sep 30, 2024 | -131.98% |
| Jun 30, 2024 | -139.20% |
| Mar 31, 2024 | -538.71% |
| Dec 31, 2023 | -170.28% |
| Sep 30, 2023 | -195.31% |
| Jun 30, 2023 | -242.46% |
| Mar 31, 2023 | -458.03% |
| Dec 31, 2022 | 523.15% |
| Sep 30, 2022 | -916.60% |
| Jun 30, 2022 | -497.42% |
| Mar 31, 2022 | -3,517.42% |
| Dec 31, 2021 | -2,806.22% |
| Sep 30, 2021 | -4,303.50% |
| Jun 30, 2021 | -14,756.20% |
| Mar 31, 2021 | -98,280.00% |